On January 28, 2019, ReShape Lifesciences Inc. announced that Dan W. Gladney has decided to resign from his role as President and Chief Executive Officer of the company effective as of March 31, 2019. Mr. Gladney will continue to serve as Chairman of the Board of the company. The company's Board of Directors will immediately begin to search for the company's next President and Chief Executive Officer.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.186 USD | -1.06% | +0.43% | -25.51% |
15/05 | Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024 | |
15/05 | Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q1 Revenue $1.9M, vs. Street Est of $2.1M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.51% | 4.41M | |
+7.41% | 223B | |
+11.63% | 195B | |
+18.64% | 144B | |
+30.01% | 111B | |
+2.32% | 65.19B | |
+14.03% | 53.02B | |
+2.68% | 50.28B | |
+7.03% | 44.15B | |
+2.48% | 36.45B |
- Stock Market
- Equities
- RSLS Stock
- News ReShape Lifesciences Inc.
- Dan W. Gladney to Resign as President and Chief Executive Officer of Reshape Lifesciences Inc., Effective as of March 31, 2019